INTRODUCTION:The morphologic and physiologic changes with use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to the dermatologic surgery community. More specifically, many patients note changes in periorificial appearance relating to inadvertent cosmetic and oral health concerns that span not only dermatology but also dentistry. This article explores the overlap between the dentistry and dermatology fields in managing effects of this class of medications. METHODS:The available peer-reviewed literature evaluating perioral changes and impacts of the GLP1RAs was evaluated in the PubMed database. RESULTS:The findings from the review of the peer-reviewed literature were limited. These findings were combined with clinical experience and reports from related topics to identify culprits for the clinical findings including but not limited to skin changes, volume loss, xerostomia, and periodontal changes. In addition, opportunities for collaborative efforts for patient care were explored. DISCUSSION/CONCLUSION:The benefit of a collaborative effort of dermatologic surgeons and dentists is demonstrated. This multidisciplinary collaboration can yield comprehensive solutions to some of the less desirable adverse effects of GLP1RAs.
BACKGROUND AND OBJECTIVES:The demand for male aesthetic treatments continues to rise, and with increased utilization of the glucagon-like peptide-1 receptor agonists (GLP-1RAs), we anticipate a growing need to address these concerns. This narrative review examined the intersection of skin-related effects of GLP-1RAs and male aesthetics, focusing on the role of the dermatologic surgeon in their management. METHODS:A search of the available peer-reviewed literature through March 2026 in the PubMed database was conducted. Search terms included combinations of terms related to GLP-1RAs, male aesthetics, and dermatologic treatments. Studies were included if they were peer-reviewed, published in English, and relevant to the topic. RESULTS:Many concerns that drive men to seek aesthetic treatments overlap with secondary cutaneous manifestations of GLP-1RA treatments including hair loss, changes in facial and body volume, and skin quality and laxity. Management options include, but are not limited to, dermal fillers for volume restoration and biostimulatory agents for skin laxity, along with medical and procedural interventions for hair loss. CONCLUSION:Dermatologic surgeons are well-positioned to address GLP-1 receptor agonist-related aesthetic concerns in male patients. Practitioners should be prepared to offer evidence-based, customized treatment strategies as this population grows.
Background: Temple hollowing is characterized by a reduction of volume in the temporal fossa, which can result in a skeletonized look and contribute to an aged appearance. This study aimed to evaluate the safety and effectiveness of VYC-20L injectable gel to improve temple hollowing. Methods: Adults with minimal, moderate, or severe temple hollows were randomized 2:1 to receive VYC-20L or no treatment. Participants were followed up for 13 months for safety and effectiveness assessments. Treatment effectiveness was assessed by blinded evaluating investigators using the validated Allergan Temple Hollowing Scale (ATHS) and the Global Aesthetic Improvement Scale (GAIS), and by participants using GAIS, FACE-Q scales, and patient satisfaction questionnaires. Adverse events and injection-site responses were monitored. Results: At month 3, 80.4% of the treatment group versus 13.5% of the untreated control group achieved a 1-grade improvement or greater in both temples on the ATHS ( P < 0.0001). The ATHS responder rate remained high throughout month 13. The GAIS responder rates at month 3 (responses of improved or much improved) were high in the treatment group, as assessed by the blinded evaluating investigator (83.8%) and participants (92.9%). Furthermore, satisfaction with facial appearance and temples on the FACE-Q questionnaires increased significantly from baseline (both P < 0.0001). Adverse events and injection-site responses were mostly mild and consistent with the known safety profile of fillers. Conclusions: VYC-20L treatment showed favorable safety and effectiveness results in restoring temple volume, with significant aesthetic improvement and high participant satisfaction. Treatment effects lasted for more than a year. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
